+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Myasthenia Gravis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)- Product Image
Myasthenia Gravis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)- Product Image
New

Myasthenia Gravis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

  • PDF Icon

    Report

  • 230 Pages
  • January 2025
  • Region: Global
  • Fairfield Market Research
  • ID: 6041867
Description Jump to:
The global myasthenia gravis treatment market is projected to grow significantly at a compound annual growth rate (CAGR) of 8.2%, increasing from a value of USD 2.69 billion in 2025 to USD 4.67 billion by the end of 2032. This growth is driven by advancements in therapeutic approaches and increasing awareness of the disease.

Myasthenia Gravis (MG) is an autoimmune disorder characterized by neuromuscular dysfunction, leading to muscle weakness and fatigue. Current treatment strategies aim to enhance neuromuscular transmission and manage autoimmune responses. Therapeutic options include acetylcholinesterase inhibitors, immunosuppressants, and emerging monoclonal antibody therapies.

The rising prevalence of MG, particularly in aging populations, and the growing focus on precision medicine are key factors fueling the market expansion. Collaborative efforts between pharmaceutical companies and research institutions are accelerating the development of innovative and targeted treatments.

Key Market Drivers

Advancements in Immunotherapies:

  • Novel treatments, including monoclonal antibodies such as eculizumab and rituximab, are transforming MG management. These therapies target specific immune system components, offering precision treatment with improved outcomes.
  • Immunotherapies continue to evolve, providing advanced tools for addressing the complex immunological aspects of MG.

Rising Disease Awareness and Detection:

  • Improved diagnostic capabilities and awareness campaigns are leading to earlier identification of MG cases.
  • Increased recognition of MG by healthcare professionals and the general population supports proactive management and expands treatment demand.

Business Opportunities

Personalized Therapies:

  • Tailoring treatments to individual patient profiles using precision medicine presents significant potential for improved efficacy and reduced adverse effects. Advances in genetic understanding and immune system dynamics drive the development of personalized therapies.

Diversified Therapeutic Modalities:

  • Companies exploring novel treatment options such as gene therapies and innovative immunomodulatory agents can unlock untapped market potential. These therapies address unmet medical needs while generating new revenue streams.

Regional Analysis

Europe:

  • Europe is emerging as a dominant region due to its strategic healthcare infrastructure and supportive regulatory environment.
  • Advanced diagnostic capabilities and specialized neurological treatment centers contribute to rapid adoption of innovative therapies.
  • The proactive approach of the European Medicines Agency fosters investor confidence and accelerates research and development initiatives.

South Asia & Pacific:

  • The region is the fastest-growing market, driven by a rising MG burden, population growth, and improved healthcare awareness.
  • Awareness campaigns and initiatives encourage early diagnosis and treatment adoption, fueling market growth.

Market Challenges

Regulatory Complexities:

  • Stringent regulatory requirements for drug approvals can delay market entry for innovative therapies. Companies must navigate these challenges effectively to maintain market competitiveness.

Therapeutic Complexity:

  • MG’s heterogeneous nature necessitates personalized approaches, creating challenges in standardizing treatment protocols.

Competitive Analysis

Prominent companies leading the myasthenia gravis treatment market include:

  • Alexion Pharmaceutical Inc.
  • Grifols SA
  • Avadel Pharmaceuticals plc.
  • Novartis AG
  • Pfizer Inc.
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Bausch Health Companies Inc.
  • Shire plc.

Myasthenia Gravis Treatment Market Segmentation

By Drug Class:

  • Cholinesterase Inhibitors
  • Corticosteroids
  • Immunosuppressants
  • Intravenous Immunoglobulin (IVIg)
  • Monoclonal Antibodies

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

This product will be delivered within 1-3 business days.

Table of Contents

1. Executive Summary
1.1. Global Myasthenia Gravis Treatment Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2025
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Myasthenia Gravis Treatment Market Outlook, 2019 - 2032
3.1. Global Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032
3.1.1. Key Highlights
3.1.1.1. Corticosteroids
3.1.1.2. IVIg
3.1.1.3. Monoclonal Antibodies
3.1.1.4. Immunosuppressants
3.1.1.5. Cholinesterase Inhibitors
3.2. Global Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032
3.2.1. Key Highlights
3.2.1.1. Hospital Pharmacies
3.2.1.2. Retail Pharmacies
3.2.1.3. Online Pharmacies
3.3. Global Myasthenia Gravis Treatment Market Outlook, by Region, Value (US$ Bn), 2019 - 2032
3.3.1. Key Highlights
3.3.1.1. North America
3.3.1.2. Europe
3.3.1.3. Asia Pacific
3.3.1.4. Latin America
3.3.1.5. Middle East & Africa
4. North America Myasthenia Gravis Treatment Market Outlook, 2019 - 2032
4.1. North America Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032
4.1.1. Key Highlights
4.1.1.1. Corticosteroids
4.1.1.2. IVIg
4.1.1.3. Monoclonal Antibodies
4.1.1.4. Immunosuppressants
4.1.1.5. Cholinesterase Inhibitors
4.2. North America Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032
4.2.1. Key Highlights
4.2.1.1. Hospital Pharmacies
4.2.1.2. Retail Pharmacies
4.2.1.3. Online Pharmacies
4.3. North America Myasthenia Gravis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
4.3.1. Key Highlights
4.3.1.1. Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
4.3.1.2. Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
4.3.1.3. Canada Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
4.3.1.4. Canada Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
4.3.2. BPS Analysis/Market Attractiveness Analysis
5. Europe Myasthenia Gravis Treatment Market Outlook, 2019 - 2032
5.1. Europe Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032
5.1.1. Key Highlights
5.1.1.1. Corticosteroids
5.1.1.2. IVIg
5.1.1.3. Monoclonal Antibodies
5.1.1.4. Immunosuppressants
5.1.1.5. Cholinesterase Inhibitors
5.2. Europe Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032
5.2.1. Key Highlights
5.2.1.1. Hospital Pharmacies
5.2.1.2. Retail Pharmacies
5.2.1.3. Online Pharmacies
5.3. Europe Myasthenia Gravis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
5.3.1. Key Highlights
5.3.1.1. Germany Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
5.3.1.2. Germany Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
5.3.1.3. U.K. Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
5.3.1.4. U.K. Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
5.3.1.5. France Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
5.3.1.6. France Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
5.3.1.7. Italy Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
5.3.1.8. Italy Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
5.3.1.9. Turkey Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
5.3.1.10. Turkey Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
5.3.1.11. Russia Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
5.3.1.12. Russia Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
5.3.1.13. Rest of Europe Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
5.3.1.14. Rest of Europe Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
5.3.2. BPS Analysis/Market Attractiveness Analysis
6. Asia Pacific Myasthenia Gravis Treatment Market Outlook, 2019 - 2032
6.1. Asia Pacific Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032
6.1.1. Key Highlights
6.1.1.1. Corticosteroids
6.1.1.2. IVIg
6.1.1.3. Monoclonal Antibodies
6.1.1.4. Immunosuppressants
6.1.1.5. Cholinesterase Inhibitors
6.2. Asia Pacific Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032
6.2.1. Key Highlights
6.2.1.1. Hospital Pharmacies
6.2.1.2. Retail Pharmacies
6.2.1.3. Online Pharmacies
6.3. Asia Pacific Myasthenia Gravis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
6.3.1. Key Highlights
6.3.1.1. China Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
6.3.1.2. China Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
6.3.1.3. Japan Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
6.3.1.4. Japan Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
6.3.1.5. South Korea Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
6.3.1.6. South Korea Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
6.3.1.7. India Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
6.3.1.8. India Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
6.3.1.9. Southeast Asia Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
6.3.1.10. Southeast Asia Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
6.3.1.11. Rest of Asia Pacific Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
6.3.1.12. Rest of Asia Pacific Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
6.3.2. BPS Analysis/Market Attractiveness Analysis
7. Latin America Myasthenia Gravis Treatment Market Outlook, 2019 - 2032
7.1. Latin America Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032
7.1.1. Key Highlights
7.1.1.1. Corticosteroids
7.1.1.2. IVIg
7.1.1.3. Monoclonal Antibodies
7.1.1.4. Immunosuppressants
7.1.1.5. Cholinesterase Inhibitors
7.2. Latin America Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032
7.2.1. Key Highlights
7.2.1.1. Hospital Pharmacies
7.2.1.2. Retail Pharmacies
7.2.1.3. Online Pharmacies
7.3. Latin America Myasthenia Gravis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
7.3.1. Key Highlights
7.3.1.1. Brazil Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
7.3.1.2. Brazil Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
7.3.1.3. Mexico Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
7.3.1.4. Mexico Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
7.3.1.5. Argentina Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
7.3.1.6. Argentina Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
7.3.1.7. Rest of Latin America Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
7.3.1.8. Rest of Latin America Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
7.3.2. BPS Analysis/Market Attractiveness Analysis
8. Middle East & Africa Myasthenia Gravis Treatment Market Outlook, 2019 - 2032
8.1. Middle East & Africa Myasthenia Gravis Treatment Market Outlook, By Drug Class, Value (US$ Bn), 2019 - 2032
8.1.1. Key Highlights
8.1.1.1. Corticosteroids
8.1.1.2. IVIg
8.1.1.3. Monoclonal Antibodies
8.1.1.4. Immunosuppressants
8.1.1.5. Cholinesterase Inhibitors
8.2. Middle East & Africa Myasthenia Gravis Treatment Market Outlook, By Distribution Channel, Value (US$ Bn), 2019 - 2032
8.2.1. Key Highlights
8.2.1.1. Hospital Pharmacies
8.2.1.2. Retail Pharmacies
8.2.1.3. Online Pharmacies
8.3. Middle East & Africa Myasthenia Gravis Treatment Market Outlook, by Country, Value (US$ Bn), 2019 - 2032
8.3.1. Key Highlights
8.3.1.1. GCC Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
8.3.1.2. GCC Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
8.3.1.3. South Africa Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
8.3.1.4. South Africa Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
8.3.1.5. Egypt Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
8.3.1.6. Egypt Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
8.3.1.7. Nigeria Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
8.3.1.8. Nigeria Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
8.3.1.9. Rest of Middle East & Africa Myasthenia Gravis Treatment Market By Drug Class, Value (US$ Bn), 2019 - 2032
8.3.1.10. Rest of Middle East & Africa Myasthenia Gravis Treatment Market By Distribution Channel, Value (US$ Bn), 2019 - 2032
8.3.2. BPS Analysis/Market Attractiveness Analysis
9. Competitive Landscape
9.1. Company Market Share Analysis, 2025
9.2. Competitive Dashboard
9.3. Company Profiles
9.3.1. Grifols SA
9.3.1.1. Company Overview
9.3.1.2. Product Portfolio
9.3.1.3. Financial Overview
9.3.1.4. Business Strategies and Development
9.3.2. Pfizer, Inc.
9.3.2.1. Company Overview
9.3.2.2. Product Portfolio
9.3.2.3. Financial Overview
9.3.2.4. Business Strategies and Development
9.3.3. AbbVie Inc.
9.3.3.1. Company Overview
9.3.3.2. Product Portfolio
9.3.3.3. Financial Overview
9.3.3.4. Business Strategies and Development
9.3.4. GSK
9.3.4.1. Company Overview
9.3.4.2. Product Portfolio
9.3.4.3. Financial Overview
9.3.4.4. Business Strategies and Development
9.3.5. Novartis AG
9.3.5.1. Company Overview
9.3.5.2. Product Portfolio
9.3.5.3. Financial Overview
9.3.5.4. Business Strategies and Development
9.3.6. Alexion Pharmaceutical Inc.
9.3.6.1. Company Overview
9.3.6.2. Product Portfolio
9.3.6.3. Financial Overview
9.3.6.4. Business Strategies and Development
9.3.7. F. Hoffman-La Roche Ltd.
9.3.7.1. Company Overview
9.3.7.2. Product Portfolio
9.3.7.3. Financial Overview
9.3.7.4. Business Strategies and Development
9.3.8. Bausch Health Companies Inc.
9.3.8.1. Company Overview
9.3.8.2. Product Portfolio
9.3.8.3. Financial Overview
9.3.8.4. Business Strategies and Development
9.3.9. Shire plc.
9.3.9.1. Company Overview
9.3.9.2. Product Portfolio
9.3.9.3. Financial Overview
9.3.9.4. Business Strategies and Development
9.3.10. Avadel Pharmaceuticals plc.
9.3.10.1. Company Overview
9.3.10.2. Product Portfolio
9.3.10.3. Financial Overview
9.3.10.4. Business Strategies and Development
10. Appendix
10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned

  • Alexion Pharmaceutical Inc.
  • Grifols SA
  • Avadel Pharmaceuticals plc.
  • Novartis AG
  • Pfizer; Inc.
  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Bausch Health Companies Inc.
  • Shire plc.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Myasthenia Gravis Treatment - Global Strategic Business Report - Product Image

Myasthenia Gravis Treatment - Global Strategic Business Report

  • Report
  • 89 Pages
  • Global
From
Myasthenia Gravis Drugs - Global Strategic Business Report - Product Image

Myasthenia Gravis Drugs - Global Strategic Business Report

  • Report
  • 182 Pages
  • Global
From
Myasthenia Gravis - Epidemiology Forecast - 2034 - Product Image

Myasthenia Gravis - Epidemiology Forecast - 2034

  • Report
  • 143 Pages
  • Global
From
Myasthenia Gravis Treatment Global Market Report 2024 - Product Image

Myasthenia Gravis Treatment Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Myasthenia Gravis Treatment Market by Type, End-User - Global Forecast 2025-2030 - Product Image

Myasthenia Gravis Treatment Market by Type, End-User - Global Forecast 2025-2030

  • Report
  • 196 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.